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Increased understanding of the precise molecular mechanisms in-
volved in cell survival and cell death signaling pathways offers the
promise of harnessing these molecules to eliminate cancer cells
without damaging normal cells. Tyrosine kinase oncoproteins pro-
mote the genesis of leukemias through both increased cell prolif-
eration and inhibition of apoptotic cell death. Although tyrosine
kinase inhibitors, such as the BCR-ABL inhibitor imatinib, have demon-
strated remarkable efficacy in the clinic, drug-resistant leukemias
emerge in some patients because of either the acquisition of point
mutations or amplification of the tyrosine kinase, resulting in a poor
long-term prognosis. Here, we exploit the molecular mechanisms of
caspase activation and tyrosine kinase/adaptor protein signaling to
forge a unique approach for selectively killing leukemic cells through
the forcible induction of apoptosis. We have engineered caspase var-
iants that can directly be activated in response to BCR-ABL. Because
we harness, rather than inhibit, the activity of leukemogenic kinases
to kill transformed cells, this approach selectively eliminates leukemic
cells regardless of drug-resistant mutations.
dimerization | phosphorylation
The activated fusion kinase BCR-ABL that causes chronicmyeloid leukemia (CML) both increases cell proliferation and
inhibits apoptosis (1, 2). Current therapies for tyrosine kinase-
driven leukemias are based on inhibiting the aberrant tyrosine
kinase activity with small molecule tyrosine kinase inhibitors
(TKIs), such as imatinib. However, TKIs can lose efficacy because
of pointmutations or amplification of the tyrosine kinase, resulting
in relapse and a poor long-term prognosis (3, 4). Additionally,
because CML stem cells are innately resistant to TKIs, these drugs
are not curative (5, 6). Therefore, there is a clinical need for an
alternative approach to selectively targeting CML cells to treat
resistant disease and eradicate residual leukemia.
Many chemotherapeutic agents trigger apoptotic cell death by
activating a family of cysteine proteases called caspases (7).
Upon receipt of apoptotic stimuli, initiator caspases are acti-
vated. For instance, the initiator caspase-8 is activated through
the formation of death-inducing signaling complexes (DISC) in
response to engagement of extracellular ligands by cell surface
death receptors such as CD95 or TNFR1. Likewise, activation of
caspase-9 is mediated by the assembly of the caspase-activating
complex apoptosome after the release of cytochrome c from the
mitochondrial intermembrane space to the cytoplasm. Once
activated, initiator caspases can cleave and activate the zymo-
genic forms of executioner caspases (e.g., caspase-3), leading to
the proteolytic cleavage of specific apoptotic substrates and, ul-
timately, the dismantling of the cell. Importantly, activation of
initiator caspases is driven by “induced proximity”; initiator
caspases-8 and -9 are activated when individual molecules are
brought into close proximity with one another through the for-
mation of the DISC or apoptosome platform, respectively (8–
11). Accordingly, artificial dimerization of initiator caspases can
also trigger their activation without assembly of the DISC or
apoptosome (12). Because multiple apoptotic pathways that lead
to caspase activation are inhibited in CML, it would be optimal
to activate caspases outside of the normal cell death pathways;
we hypothesized that forcible dimerization of initiator caspases
that can be induced in a BCR-ABL–dependent manner regard-
less of drug resistance would circumvent these loci of inhibition,
providing a valuable tool for selectively killing leukemic cells.
Results and Discussion
We embarked on the design of a caspase variant that could be
activated specifically in response to BCR-ABL activity. As shown
in Fig. 1A, this construct, termed “iCaspase-8” (inducible cas-
pase-8), consists of the adaptor protein Crk flanked by two
copies of caspase-8 (protease domain without the prodomain).
In this caspase variant, phosphorylation of Tyr-221 on Crk (Tyr-
222 on chicken Crk used in the present study) by BCR-ABL was
expected to cause a conformational change in Crk resulting from
intramolecular binding of pTyr-221 to the Crk SH2 domain (13).
We anticipated that the caspase-8 moieties would then be juxta-
posed in close proximity, thereby triggering the intramolecular
dimerization of caspase-8 (13). It has been reported that BCR-
ABL exhibits different substrate preferences than its normal cel-
lular counterpart, c-ABL (14, 15). Thus, although every cell con-
tains tyrosine kinases, we expected that the significantly higher
level of BCR-ABL kinase activity in transformed cells, combined
with the slightly altered substrate specificity, would trigger selec-
tive activation of the caspase constructs in transformed cells. In
normal cells, construct dimerization would be very inefficient and
the proteins should be innocuous. As predicted by this model,
expression of iCaspase-8 triggered massive apoptotic death in the
BCR-ABL–positive patient-derived human cell line K562 (Fig.
1B). iCaspase-8 also specifically killed Ba/F3 cells stably expressing
BCR-ABL (Fig. 1 C and D and Fig. S1 A and B). Importantly,
iCaspase-8 did not induce apoptosis in normal Ba/F3 cells (Fig. 1
C and D). Moreover, because Crk is not phosphorylated on Y221
in cells expressing the leukemic oncoproteins, FLT3D835Y (found in
acute myeloid leukemia; ref. 16) or TEL-PDGFRβ (found in
chronic myelomonocytic leukemia; ref. 17), iCaspase-8 did not kill
Ba/F3 cells expressing these activated tyrosine kinases (Fig. 1 C–E
and Fig. S1D and E). The subcellular localization of iCaspase 8 was
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the same (cytoplasmic) in both the Ba/F3 cells and Ba/F3 cells
transformed with activated tyrosine kinases (Fig. S1F). Importantly,
iCaspase-8 carrying aY221Fmutation (iCaspase-8Y/F) did not cause
cell death in BCR-ABL–expressing cells, and, when one of the
caspase-8 moieties was replaced with a catalytically inactive mutant
(C/S), the mutant iCaspase-8 (iCaspase-8C/S) was significantly
reduced in its ability to kill BCR-ABL–transformed Ba/F3 cells
(Fig. 1C andD and Fig. S1C). Moreover, expression of the inactive
iCaspase-8 mutants affected neither cell proliferation (Fig. S2A)
nor clonogenic survival (Fig. S2B) of BCR-ABL–positive cells.
In that iCaspase-8 did not kill Ba/F3 cells expressing endoge-
nous c-ABL, it seemed likely that resting levels of c-ABL could not
phosphorylate and activate iCaspase-8 sufficiently to induce cell
death. However, because the ultimate goal of our approach is to
eliminate leukemic cells while sparing normal hematopoietic cells,
it was important to confirm that the transient activation of c-ABL
associated with normal cell signaling could not activate iCaspase-
8. T-cell activation is well known to result in c-ABL activation (18,
19). To model the effects of this process on iCaspase-8 activation,
Jurkat cells stably expressing empty vector or iCaspase-8 were
treated with anti-CD3 and anti-CD28 antibodies. Although CD3/
CD28 stimulation resulted in rapid c-ABL activation, it did not
lead to cell death mediated by iCaspase-8 (Fig. S3A andB). Taken
together, these findings show that iCaspase-8 functions as a BCR-
ABL–specific cell death activator.
To explore this approach further, we also created a caspase-9
version of the construct, named iCaspase-9 (Fig. S4A). iCaspase-
9 also triggered apoptosis in BCR-ABL–expressing cells (Fig.
S4B). Nevertheless, compared with iCaspase-8, the efficacy of
iCaspase-9 was rather low (Fig. S4 B and C). This result is
consistent with previous reports that caspase-9 requires docking
on the Apaf-1 apoptosome for full activity (20, 21). Given that the
initiator caspases-8 and -9 are activated by assembly of the DISC
and apoptosome, respectively, we also sought to test an alterna-
tive approach to using the iCaspase strategy, in which endogenous
initiator caspases would be forcibly activated in a BCR-ABL–
dependent manner. We hoped that this approach would further
safeguard against inappropriate activation in normal cells where
unplanned dimerization of the exogenous caspase constructs
might occur. We engineered constructs where Crk is flanked on
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Fig. 1. iCaspase-8 specifically triggers apoptosis in cells expressing BCR-ABL. (A) iCaspase-8 becomes active after phosphorylation of Crk at Tyr-221 by BCR-
ABL. (B) iCaspase-8 (MSCV-IRES-GFP-WRE) was expressed in K562 cells. Forty-eight hours after infection, cell death % (with SEM) was analyzed by PI staining
(*P < 0.05 by Student t test). (C and D) Normal Ba/F3 cells, or Ba/F3 cells expressing BCR-ABL, FLT3D835Y, or TEL-PDGFRβ, were infected with a retroviral vector
(MSCV-IRES-GFP-WRE) encoding vector alone (GFP), iCaspase-8 (iC8), iCaspase-8Y/F (iC8Y/F), or iCaspase-8C/S (iC8C/S). Forty-eight hours after infection, the cells
were fixed, stained with anti-cleaved caspase 3-antibody (Alexa 647), and analyzed by flow cytometry. Shown are representative flow cytometry plots (C) and
average cell death %with SEM (% cells with cleaved-caspase-3 signal) in the GFP-positive population (D; *P < 0.05 GFP vs. iC8 by Student’s t test). (E) Ba/F3 cell
lysates were subjected to immunoblotting with anti–pan-Crk and anti–phospho-Tyr-221 antibodies.
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either side by the caspase recruitment domain (CARD) of the
adaptor protein Apaf-1 (iApoptosome) or the death effector
domain (DED) of the adaptor protein FADD (iDISC). Analo-
gous to the scenario with iCaspase, phosphorylation of Tyr-221 on
Crk by BCR-ABL would be expected to juxtapose the two CARD
or DED moieties, which would, in turn, recruit and activate en-
dogenous caspase-9 or caspase-8, respectively (Fig. S5A). How-
ever, we found that the iApoptosome was not as effective as
iCaspase-8 or iCaspase-9 for reasons we do not fully understand
and the iDISC triggered nonspecific cell death even in normal Ba/
F3 cells (Fig. S5B). We therefore focused on iCaspase-8 as the
most promising BCR-ABL–dependent inducer of cell death.
To demonstrate that iCaspase-8 activation was caused by
intramolecular, not intermolecular, dimerization of the caspase-8
protease domain, we examined the status of iCaspase-8 by size-
exclusion chromatography.When expressed in normal Ba/F3 cells,
iCaspase-8 was detected in the fractions corresponding to its
expected molecular mass (∼100 kDa) (Fig. 2 A and B and Fig. S6).
When expressed in BCR-ABL–transformed Ba/F3 cells, iCaspase-
8 was detected at 70 kDa by immunoblotting, indicating that ac-
tivated iCaspase-8 underwent proteolytic processing between the
small and large subunits of the protease domains (Fig. 2 A and B
and Fig. S6). Nevertheless, upon size-exclusion chromatography,
the cleaved iCaspase-8 was detected in the same column fractions
as the full-length iCaspase-8, as would be expected because the
subunits should remain associated in the mature enzyme. When
iCaspase-8Y/F was expressed in BCR-ABL–transformed Ba/F3
cells, the cleavage was not observed (Fig. 2B). These data are fully
consistent with the idea that iCaspase-8 is activated through in-
tramolecular dimerization.
We next tested whether iCaspase-8 could eliminate BCR-ABL–
positive cells from a heterogeneous population without impeding
the growth and survival of normal cells. iCaspase-8 was expressed
bicistronically with GFP in a mixed population of normal (90%)
and BCR-ABL–expressing (10%) Ba/F3 cells. GFP-positive cells
were sorted by FACS 48 h after infection with iCaspase-8, and
quantitative real-time PCR (qPCR) was performed on day 7 to
detect the BCR-ABL message present in the population (Fig. 3).
Remarkably, by day 7, the BCR-ABL mRNA decreased to nearly
undetectable levels in the iCaspase-8–treated population (Fig. 3).
These results indicate that iCaspase-8 can eliminate BCR-ABL–
positive cells from a cell mixture without markedly decreasing the
viability/proliferation of normal cells.
To further examine the efficacy of iCaspase-8, we performed
colony forming assays by using primary hematopoietic stem cells
(HSCs). Mouse HSC-enriched populations (c-Kit+ Lin− Sca-1+ or
KLS) were isolated from bone marrow and were cotransduced
with BCR-ABL and iCaspase-8 bicistronically expressed with
GFP and YFP, respectively. GFP-YFP double-positive cells were
selected by FACS and plated in methylcellulose medium. BCR-
ABL–positive cells formed greatly reduced colony numbers when
coinfected with iCaspase-8 compared with control vector (YFP)
(Fig. 4A and Fig. S7A). Most importantly, however, iCaspase-8
significantly diminished leukemia cell colony formation even
when BCR-ABL carried kinase domain mutations commonly
arising in the setting of imatinib resistance (Fig. 4A and Fig. S7 A
and B). Furthermore, expression of iCaspase-8 in naïve KLS cells
did not affect cell growth in vitro relative to controls (Fig. 4B and
Fig. S7C). Note that iCaspase-8 and imatinib were slightly syn-
ergistic in the presence of WT BCR-ABL. This result is likely
due to residual BCR-ABL activity that persisted at the dose of 2
μM (Fig. S7D). Indeed, colonies still formed even in the
presence of imatinib (approximately 10% compared with
control; Fig. 4A and Fig. S7E). It is possible that any residual
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Fig. 2. iCaspase-8 activation is caused by intramolecular dimerization. (A)
Schematic diagram of iCaspase-8. Each of the two caspase-8 moieties is
composed of the small (S) and large (L) subunits. The linker connecting the
two subunits will be autoprocessed upon activation of iCaspase-8, resulting in
10-, 20-, and 70-kDa proteolytic fragments. (B) iCaspase-8 or iCaspase-8Y/F was
expressed in Ba/F3 cells (control or BCR-ABL). Forty-eight hours after in-
fection, cell lysates were prepared and loaded onto a Supedex-200 column.
Each chromatographic fraction was collected and subjected to immunoblotting
with anti-human Caspase-8 antibody to detect iCaspase-8. Intact and cleaved
iCaspase-8 is shown by an arrow and an arrowhead, respectively.
x 103 Cells
Day
0
5
10
15
20
25
30
GFP iC8
B
C
R
-A
B
L/
A
ct
in
qPCRFACS
(GFP+ cells)
Virus 
infection
*
0.1
1
10
100
1000
10000
100000
-2 -1 0 1 2 3 4 5 6 7
GFP iC8
P>0.05
Fig. 3. iCaspase-8 eliminates BCR-ABL–positive cells while sparing normal
cells. The mixture of Ba/F3 cells (normal:BCR-ABL = 9:1) was infected with an
empty vector or iCaspase-8 (MSCV-IRES-GFP-WRE), and FACS sorted to select
GFP-positive cells. The sorted cells were further cultured for 7 d and analyzed
by qPCR for the BCR-ABL message. qPCR results were normalized against
actin (Right; *P < 0.05 by Student’s t test). The experiments were repeated
four times, and there was no significant difference in cell growth between
the two groups (Left; P > 0.05 by Student’s t test). Error bars are SEM.
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BCR-ABL activity results in activation of iCaspase-8, leading to
the observed synergy. In line with this hypothesis, no such synergy
was observed in the presence of the imatinib-resistant BCR-ABL
mutants (Fig. 4A).
iCapsase-8 was next tested most stringently in the setting of
blast crisis CML. We generated mice with blast crisis CML driven
by BCR-ABL and NUP98-HOXA9 (22, 23). The lineage-nega-
tive fraction (Lin−) of BCR-ABL+ NUP98-HOXA9+ cells were
isolated from the mouse spleens and transduced with control
vector or iCaspase-8 expressed bicistronically with GFP. iCas-
pase-8, but not control vector, triggered massive apoptosis in
BCR-ABL–expressing cells (Fig. S8 A and B). GFP-positive cells
were further sorted by FACS for colony forming assays. As shown
in Fig. 5A (also Fig. S7F), expression of iCaspase-8 significantly
impaired clonogenic growth of the leukemic cells in vitro. We also
transplanted the KLS cells into congenic mouse recipients after
iCaspase-8 transduction. iCaspase-8 significantly suppressed blast
crisis CML development in vivo (Fig. 5B; 96% control versus 40%
iCaspase-8, P < 0.05) and its associated splenomegaly (Fig. 5 C
and D). These results indicate that iCaspase-8 is highly effective
in the established blast crisis form of disease.
We further tested whether iCaspase-8 could also kill human
leukemia cells. We expressed iCaspase-8 in primary CD34+ cells
isolated from five independent patients with blast crisis CML
(according to the preparation scheme shown in Fig. 6A). As shown
in Fig. 6B, iCaspase-8 caused significant cell death in the primary
cells, compared with vector control (GFP). To analyze the efficacy
of iCaspase-8 in both stem and progenitor populations, CD34+
cells were also loaded with CellTrace Violet. Importantly, ex-
pression of iCaspase-8 resulted in apoptosis in both dividing and
nondividing populations, indicating that iCaspase-8 can induce
apoptosis in quiescent CML stem cells, which is resistant to TKIs
(7) (Fig. 6C).
In this study, we took a unique approach to selectively killing leu-
kemia cells through the forcible induction of apoptosis. iCaspase-8
canbeactivated inamannerdependenton thekinaseactivityofBCR-
ABL. Therefore, BCR-ABL–positive cells were selectively elimi-
nated regardless of the presence of imatinib-resistantmutations. This
approach may be particularly important in autologous bone mar-
row transplantation, where contamination of the graft with leu-
kemia cells contributes to relapse and defines a need for more
effective and selective purging strategies. Although autologous
transplant is less frequently used in CML than before the in-
troduction of tyrosine kinase inhibitors, it remains a salvage option
for patients who have failed other therapies. Toward optimizing
the purging effect, it still remains to be fully determined why
a small proportion of BCR-ABL–positive cells survived in vitro
and in vivo even after iCaspase-8 expression (Fig. 5). Because
these “escapers” were associated with low iCaspase8 expression
(Fig. S9), more robust delivery and expression system might fur-
ther strengthen the efficacy of iCaspase-8. In addition, because it
would bebest to restrict iCaspase-8 expression to the time required
to kill leukemic cells in vitro before transplantation, our proce-
dure could ultimately be modified for use with less stable, non-
integrating vectors or direct “protein” delivery, decreasing the
chances of unwanted side effects. Moreover, although the con-
structs described here were tailored for BCR-ABL–positive leu-
kemias, they establish proof of principle. Thus, it should be
possible to alter the tyrosine phosphorylation site and SH2 within
the linker separating the two capsase-8 moieties to design similar
constructs for other tyrosine kinase-driven leukemias.
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Fig. 4. iCaspase-8 selectively kills BCR-ABL–positive mouse HSCs. (A) Mouse
KLS cells were cotransduced with BCR-ABL (MSCV-IRES-GFP) and iCapsase-8
(MSCV-IRES-YFP-WRE) or empty vector. BCR-ABL was either wild type (WT) or
carried an imatinib-resistantmutation (E255K, T315I,M351T). GFP-YFP double-
positive cells were further selected by FACS and plated in methylcellulose
mediumwith or without 2 μM imatinib. The colony numbers were counted 7 d
after plating (*P < 0.05 YFP vs. iC8 by Student t test). (B) Mouse KLS cells were
transduced with iCapsase-8 (MSCV-IRES-GFP-WRE) or empty vector. GFP posi-
tive cells were selected by FACS and plated in methylcellulose medium. The
colonynumberswere counted 7 d after plating. Averageswith SEMare shown.
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Fig. 5. iCaspase-8 selectively kills blast crisis CML cells in
mouse. (A) Lin− BCR-ABL+ NUP98-HOXA9+ cells isolated from
mice with blast crisis CML were infected with control vector or
iCaspase-8 (MSCV-IRES-GFP-WRE). Forty-eight hours after in-
fection, GFP and YFP (BCR-ABL) coexpressing cells were se-
lected and plated in methylcellulose medium for colony
forming assays. The colony numbers were counted 7 d after
plating. Average colony numbers with SEM are shown (*P <
0.05 by Student’s t test). (B) Cells infected with BCR-ABL,
NUP98-HOXA9, and either control vector or iCaspase-8 were
transplanted and survival was monitored (control, n = 23;
iCaspase-8, n = 20; *P < 0.05 by Kaplan–Meier analysis with
log-rank test). (C and D) Spleens were collected from each
mouse and weighed (C). Average weights and SEM are shown
(*P < 0.05 by Student’s t test). Representative spleens are
shown in D: spleens from control (Left) and iCaspase-8 mice
[surviving mice (Center) and leukemic mice (Right)].
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Materials and Methods
Plasmid Construction iCaspase-8, iCaspase-9, iApoptosome, and iDISC were
cloned intoMSCV vectors that contain theWRE element and a bicistronic IRES-
GFP or -YFP (MSCV-IRES-GFP-WRE or MSCV-IRES-YFP-WRE) (Addgene plasmid
12282; ref. 24). For human primary cell experiments, iCaspase-8 was cloned
into the lentiviral vector pCDH-EF1-IRES-GFP (System Biosciences). iCaspase-8
consists of human caspase-8 protease domain (residues 206–479) and full-
length chicken Crk. The C-terminal end of the caspase-8 protease domain was
connected to the N-terminal end of Crk by a linker sequence (N-GGGGG-
GSGGGGGG-C); the C-terminal end of Crk was connected to the N terminus of
the caspase-8 protease domain by a linker (N-GGGGGGRGGGGGGGGGG-C).
Similarly, iCaspase-9 consists of human caspase-9 protease domain (residues
139–416) and chicken Crk. iApoptosome and iDISC were created by replacing
the protease domain with the CARD of human Apaf-1 (residues 1–90) and the
DED of mouse FADD (residues 1–85), respectively. All point mutations (iCas-
pase-8Y/F and iCaspase-8C/S) were generated with the QuikChange mutagen-
esis kit (Stratagene).
BCR-ABL and its kinase domain mutants were cloned into MSCV vectors
(MSCV-IRES-GFP or -YFP; ref. 25). NUP98-HOXA9 was cloned into the MSCV-
IRES-t-hNGFR vector (23).
Reagents and Antibodies. The antibodies used were as follows: anti-Crk
antibody (BD Transduction Laboratories), anti–phospho-Crk (phospho Y221)
antibody, anti-Lamin B1 antibody (Abcam), anti-cleaved caspase-3 antibody,
anti-human caspase-8 antibody, Streptavidin-APC (BD Biosciences), biotin-con-
jugated anti-humanCD271 (hNGFR) (BD Pharmingen), anti–caspase-8 antibody,
anti-CrkL antibody, anti–phospho-CrkL (phospho Y207) antibody (Cell Signal-
ing), anti-mouse c-Kit, Sca-1, Ter119, Mac-1, Gr-1, B220, CD3, CD4, CD8, anti-
human CD3, and CD28 (eBiosciences), anti-IκB-α antibody (Santa Cruz Bio-
technology), and goat anti-rabbit Alexa Fluor 647 (Molecular Probes).
Interleukin-3 (IL-3) and imatinib mesylate were purchased from Peprotech
and LC Laboratories, respectively.
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific)
were used for isolation of the nuclear and cytocplasmic fractions. z-VADwere
purchased from Enzo Life Sciences.
Cell Culture. Control and Ba/F3 cells expressing BCR-ABL, FLT3D835Y, or TEL-
PDGFRβ were generous gifts from A. M. Pendergast (Duke University, Dur-
ham, NC) and D. G. Gilliland (Harvard Medical School, Boston, MA). Ba/F3
cells were maintained in RPMI1640 medium supplemented with 10% (vol/
vol) FBS and 1 ng/mL IL-3. K562 cells (ATCC) and Jurkat T-cells (ATCC) were
cultured in RPMI medium supplemented with 10% (vol/vol) FBS.
Mice. BA (C57BL/Ka-Thy1.1) mice were used as transplant donors, and B6-
CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) mice were used as transplant recipients
(23). All mice were 8–16 wk of age. Mice were bred and maintained in the
animal care facility at Duke University Medical Center. All animal experi-
ments were performed according to protocols approved by the Duke Uni-
versity Institutional Animal Care and Use Committee.
Apoptosis Assays. Cells were fixed by 4% formaldehyde and membrane
permeabilized by 90%methanol. The cells were stainedwith cleaved caspase-
3 antibody and with goat anti-rabbit Alexa Fluor 647 and subjected to flow
cytometric analysis. Apoptosis assays were also performed by staining live
cells with Annexin-V (conjugated to Alexa Fluor 647; Molecular Probes) and
propidium iodide (PI; Molecular Probes).
Gel filtration was performed as described (26). Control or BCR-ABL-
expressing Ba/F3 cell were infected with the retroviruses expressing iCas-
pase-8 or its inactive mutant iCaspase-8Y/F. Forty-eight hours after infection,
the cell lysate (in a volume of 250 μL) was made and loaded onto a Superdex-
200 column (GE Healthcare) at a flow rate of 0.3 mL/min.
HSC Isolation. KLS cells were isolated from mouse bone marrow as described
(23). In brief, cells enriched with c-Kit beads (Miltenyi Biotec) were stained
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Fig. 6. iCaspase-8 selectively kills patient-derived CML
cells in vitro. (A) Schematic diagram of the experi-
mental process. Ficoll-purified white blood cells were
isolated from patients with blast crisis stage of CML.
The cells were stained with PE-conjugated anti-CD34
antibody and CellTrace Violet. CD34/CellTrace Violet
double-positive cells were selected by FACS. CD34+
/CellTrace Violet+ cells were transduced with vector
control or iCaspase-8 (pCDH-EF1-IRES-GFP). Forty-eight
hours later, the cells were stained with Annexin V
(conjugated with Alexa 647). (B) Average cell death %
with SEM (% cells with Annexin V signal) in the GFP-
positive population are shown (*P < 0.05 by Student’s t
test) (C). Representative flow cytometry plots (with %
cell population) are shown (Left): Annexin V vs. Cell-
Trace Violet in GFP+ or iCaspase-8+ populations. Aver-
age cell survival % with SEM in CellTrace Violethigh and
CellTrace Violetlow populations are shown (Right; *P <
0.05 by Student t test).
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with c-Kit-APC, Sca1-PE-Cy5.5, and lineage (Lin) markers conjugated with
phycoerythrin (PE). As lineage markers, antibodies were used against murine
Ter119, Mac-1, Gr-1, B220, CD3, CD4, and CD8.
Methylcellulose Colony Formation Assays. The isolated KLS cells were cultured
overnight in X-Vivo15 media (Lonza) supplemented with 50 μM β-mercap-
toethanol, 10% (vol/vol) FBS, stem cell factor (SCF, 100 ng/mL; R&D Systems)
and thrombopoietin (TPO, 20 ng/mL; R&D Systems). Twenty-four hours after
isolation, KLS cells were infected with the retroviruses and cultured for ad-
ditional 48 h. YFP and GFP double-positive cells were selected by FACS and
plated in methylcellulose medium (M3434; Stem Cell Technologies) with or
without 2 μM imatinib mesylate. Colonies were counted 7 d after plating.
Mouse Leukemia Model. For generation of blast crisis CML in mice, KLS cells
were infected with MSCV-BCR-ABL-IRES-YFP and MSCV-NUP98-HOXA9-IRES-
t-hNGFR (23). Forty-eight hours after infection, cells coexpressing YFP and
t-hNGFR were sorted and transplanted retroorbitally into B6-CD45.1 recipient
mice, which had been sublethally irradiated (7 Gy). After transplantation,
recipient mice were maintained on antibiotic water (sulphamethoxazole and
trimethoprim) and evaluated daily for signs of morbidity, weight loss, failure
to groom, and splenomegaly. Premorbid animals were killed, and spleno-
cytes were harvested.
The isolated splenocytes were stained with lineage markers conjugated
with PE-Cy5. Donor-derived Lin− leukemia cells were selected by FACS and
cultured in X-Vivo medium as described above. Twenty-four hours later, the
cells were infected with MSCV-iCaspase-8-IRES-GFP-WRE or MSCV-IRES-GFP-
WRE. Forty-eight hours after infection, GFP+ cells were selected by FACS and
transplanted retroorbitally into sublethally irradiated (7 Gy) B6-CD45.1 mice
(3,000 cells per mouse). After transplantation, recipient mice were moni-
tored for signs of morbidity as described above.
Jurkat T-Cell Stimulation. Jurkat T cells were infected with retrovirus
expressing iCaspase8 or GFP alone. GFP-positive cells were sorted and then
stimulated for 18 h on plates coated with 5 μg/mL anti-CD3 and anti-CD28
antibodies. Cell death was then assayed by PI exclusion.
qPCR Analysis. RNA was isolated by using RNAqueous-Micro (Ambion). Equal
amounts of RNAs were converted to cDNA by using SuperScript II reverse
transcriptase (Invitrogen). qPCRs were performed by using an iCycler (BioRad)
by mixing cDNAs, iQ SYBRGreen Supermix (Bio-Rad), and gene-specific pri-
mers. Results were normalized to the level of β-actin (Actb, mouse) or β2
microglobulin (B2m, mouse). Primer sequences are as follows: BCR-ABL-F, 5′-
TCCACTCAGCCACTGGATTTAA-3′; BCR-ABL-R, 5′-TGAGGCTCAAAGTCAGAT-
GCTACT-3′; iCaspase-8-F (human caspase-8), 5′-AAATGAAAAGCAAACCTCG-
GG-3′; iCaspase-8-R (human caspase-8), 5′-CTTCAAAGGTCGTGGTCAAAG-3′;
Actin-F, 5′-TTCGTTGCCGGTCCACA-3′; Actin-R, 5′-ACCAGCGCAGCGATATCG-
3′; B2m-F, 5′-ACCGGCCTGTATGCTATCCAGAA-3′; B2m-R, 5′-AATGTGAGGC-
GGGTGGAACTGT-3.
Human CML Experiments. Studies on primary human CML samples were carried
out with approval from the Duke University Institutional Review Board. The
Ficoll-Paque-purified cells were stained with anti-CD34 conjugated with PE
(Miltenyi Biotec) and CellTraceViolet (Life Technologies). CD34/CellTrace double-
positive cells were selected by FACS and cultured overnight in X-Vivo15 media
supplemented with 50 μM β-mercaptoethanol, 10% FBS, 10 ng/mL SCF, 20 ng/
mL TPO, and 10 ng/mL FLT3L (R&D Systems). Twenty-four hours later, the cells
were infected with the lentiviruses (pCDH) and cultured for additional 48 h.
Statistical Analysis. The statistical analysis was carried out by using the R
language version 2.6.2 (www.r-project.org) and GraphPad Prism software
version 4.0c (GraphPad Software).
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